Liposorber

Liposorber LIPOSORBER therapy removes LDL-C and Lp(a) from the blood and is indicated for FH and FSGS patients.

September 15th is Apheresis Awareness Day, and we're recognizing patients, nurses, physicians, and treatment teams who r...
09/15/2026

September 15th is Apheresis Awareness Day, and we're recognizing patients, nurses, physicians, and treatment teams who rely on apheresis therapies to manage serious conditions.

Did you know that LIPOSORBER® is the only FDA-approved lipoprotein apheresis system in the United States?

When diet, lifestyle changes, and medications are not enough, LIPOSORBER can help eligible patients remove LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] directly from the bloodstream.

Together, we're raising awareness of treatment options that provide hope when standard therapies fall short.

For LIPOSORBER Indications for Use and other safety information, please visit:
https://www.liposorber.com/liposorber-safety-info

💙 As we approach Apheresis Awareness Day, we're honoring the incredible teams behind every LIPOSORBER® treatment. From p...
09/15/2026

💙 As we approach Apheresis Awareness Day, we're honoring the incredible teams behind every LIPOSORBER® treatment. From physicians and nurses to coordinators, vascular access specialists, and support staff - your commitment helps transform complex treatment journeys into compassionate patient care. Apheresis care is a team effort.

Thank you for educating, monitoring, supporting, and advocating for patients every day. We appreciate all that you do!

For LIPOSORBER Indications for Use and other safety information, please visit:
https://liposorber.com/liposorber-safety-info

September 15th is Apheresis Awareness Day, and we're recognizing patients, nurses, physicians, and treatment teams who r...
09/14/2026

September 15th is Apheresis Awareness Day, and we're recognizing patients, nurses, physicians, and treatment teams who rely on apheresis therapies to manage serious
conditions.

Did you know that LIPOSORBER® is the only FDA-approved lipoprotein apheresis system in the United States? *

When diet, lifestyle changes, and medications are not enough, LIPOSORBER can help eligible patients remove LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] directly from the bloodstream.

Together, we're raising awareness of treatment options that provide hope when standard therapies fall short.

*LIPOSORBER is FDA approved for the treatment of certain high-risk patients who are clinically diagnosed with familial hypercholesterolemia (FH). It is also FDA-authorized as a Humanitarian Use Device for the treatment of patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis (FSGS).

For full LIPOSORBER Indications for Use and other safety information, please visit:
https://liposorber.com/liposorber-safety-info

❓ Frequently Asked Question: When should a patient consider LIPOSORBER®?💡 Answer: LIPOSORBER is indicated for select pat...
09/13/2026

❓ Frequently Asked Question: When should a patient consider LIPOSORBER®?
đź’ˇ Answer: LIPOSORBER is indicated for select patients with cardiovascular and/or kidney diseases (like FH and FSGS) who struggle to achieve the recommended therapeutic target goals when lifestyle changes are ineffective and maximum drug therapies are ineffective and/or not tolerated.

For LIPOSORBER Indications for Use and other safety information, please visit: liposorber.com/liposorber-safety-info

Could LIPOSORBER® be the right path forward for your health journey? 🛤️ If you are struggling with FH or FSGS and haven'...
09/11/2026

Could LIPOSORBER® be the right path forward for your health journey? 🛤️ If you are struggling with FH or FSGS and haven't found success with standard treatments, there are other options available. Visit our website to take our quick patient candidate quiz, and be sure to discuss the results with your doctor to explore your next steps. 📋⚕️
Take the quiz: https://liposorber.com/cardiovascular-disease/am-i-a-candidate-fh/
For LIPOSORBER Indications for Use and other safety information, please visit: liposorber.com/liposorber-safety-info

"When in doubt, apherese it out!" – Dr. ZaritskyOne of the memorable takeaways from Dr. Joshua Zaritsky's recent discuss...
09/11/2026

"When in doubt, apherese it out!" – Dr. Zaritsky

One of the memorable takeaways from Dr. Joshua Zaritsky's recent discussion was the ongoing exploration of how lipid apheresis therapy may benefit patients with difficult-to-treat FSGS.

The presentation reviewed several proposed effects of lipoprotein apheresis, including:
âś… Reduction of inflammatory mediators
âś… Reduction of oxidized lipid-related macrophage stimulation
âś… Potential enhancement of immunosuppressive and corticosteroid response
âś… Utility in both primary FSGS and post-transplant recurrence settings

Dr. Zaritsky also discussed the need for continued research to better understand which patients are most likely to benefit and the biological mechanisms behind treatment response.

As the nephrology community continues to investigate these questions, educational forums and peer-to-peer dialogue remain essential to advancing patient care.

Thank you to all the physicians, nurses, and healthcare professionals who joined us for these important conversations.

*LIPOSORBER is FDA-authorized under HDE for adult and pediatric patients with nephrotic syndrome associated with primary FSGS who haven’t responded to standard therapies.

For LIPOSORBER Indications for Use and other safety information, please visit:
https://www.liposorber.com/liposorber-safety-info

What makes FSGS such a challenging disease to treat?During a recent educational program, Dr. Joshua Zaritsky highlighted...
09/08/2026

What makes FSGS such a challenging disease to treat?

During a recent educational program, Dr. Joshua Zaritsky highlighted several realities that continue to challenge nephrologists treating FSGS:
• The cause of FSGS often remains unclear.
• Treatment approaches are largely empiric.
• Recurrence after kidney transplant remains a significant concern.
• Researchers continue to investigate the underlying mechanisms driving disease progression.

As our understanding of FSGS evolves, so does the opportunity to explore new approaches that may improve outcomes for patients facing resistant disease.

One of the themes emphasized during the discussion was the importance of continuing to ask why the disease occurs. He suggested that we work backwards by looking at a subset of successful patient outcomes to better understand the underlying disease mechanisms.

Advancing care starts with advancing knowledge.

*LIPOSORBER is FDA-authorized under HDE for adult and pediatric patients with nephrotic syndrome associated with primary FSGS who haven’t responded to standard therapies.

For LIPOSORBER Indications for Use and other safety information, please visit:
https://www.liposorber.com/liposorber-safety-info

Three leading institutions. One important conversation.Recently, renowned pediatric nephrologist Dr. Joshua Zaritsky, MD...
09/03/2026

Three leading institutions. One important conversation.

Recently, renowned pediatric nephrologist Dr. Joshua Zaritsky, MD, PhD, joined Kaneka and healthcare professionals at Nemours, Atlantic Health System, and New York-Presbyterian Hospital to discuss the challenges of managing refractory FSGS and the evolving role of lipoprotein apheresis.

The sessions focused on:
• The burden of FSGS
• Current treatment challenges in treatment-resistant nephrotic syndrome
• Patient selection considerations
• The role of lipoprotein apheresis as an adjunctive therapy and its potential impact on outcomes
We're grateful to the nephrologists, physicians, and nurses who participated in these discussions and continue to advance care for patients facing complex kidney diseases.

*LIPOSORBER is FDA-authorized under HDE for adult and pediatric patients with nephrotic syndrome associated with primary FSGS who haven’t responded to standard therapies.
For LIPOSORBER Indications for Use and other safety information, please visit:
https://www.liposorber.com/liposorber-safety-info

In our August Liposorber Newsletter, we learn about Leanne's story - an FH & FSGS patient who is happy to have found a t...
08/26/2026

In our August Liposorber Newsletter, we learn about Leanne's story - an FH & FSGS patient who is happy to have found a treatment option for her, we review recently attended NCVH & ASPC conferences & share recent Liposorber events & more! - https://mailchi.mp/kaneka/liposorbernewsletter-aug2026

Your journey matters, and your story can inspire others! Every LIPOSORBER® journey is a powerful testament to resilience...
08/13/2026

Your journey matters, and your story can inspire others!

Every LIPOSORBER® journey is a powerful testament to resilience, hope, and strength. By sharing your experience, you help raise awareness and build a supportive community for others navigating similar paths.

Ready to share? Scan the QR code in the image or visit qrco.de/liposorberstory to submit your story today!

Address

623 5th Avenue 27th FL
New York, NY
10022

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

(800)5263522

Website

Alerts

Be the first to know and let us send you an email when Liposorber posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Category